- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2020–2022 · career development · K99
Identifying drug synergistic with cancer immunotherapy
Avinash Das Sahu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2023 · career development · K22
Repurposing Metformin for the Prevention of Disease Progression in Precursor Multiple Myeloma
Catherine Marinac · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · research · R01
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer
Kai W Wucherpfennig · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · research · R37
Molecular mechanisms underlying lineage plasticity in prostate cancer
Himisha Beltran · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2021 · career development · K08
Defining mechanisms of thalidomide analog resistance
Adam Sperling · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2026 · program · P01
New therapeutic vulnerabilities in breast cancer
Kornelia Polyak · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · program · P01
New therapeutic vulnerabilities in breast cancer
Kornelia Polyak · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · research · R50
Single cell investigation of co-evolution in cancer cells and host cell immune microenvironment
Shuqiang Li · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · career development · K08
Enhancing Venetoclax Activity in Chemoresistant Acute Myeloid Leukemia
Jacqueline Suen Garcia · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · research · R01
Translation of a Bismuth-Gadolinium Nanoparticle for MR-guided Radiation Therapy
Ross I. Berbeco · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · career development · K08
Enhancing Venetoclax Activity in Chemoresistant Acute Myeloid Leukemia
Jacqueline Suen Garcia · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2023 · research · R01
Comprehensive genomic profiling of aggressive hormone sensitive prostate cancer
Christopher J Sweeney · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · program · P50
Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant
Cesar M Castro · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · research · R00
De novo design of small-molecule-binding proteins
Nicholas Polizzi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · grant · DP5
Dissecting the interaction between DNA damage repair defects and the tumor microenvironment
Sarah James Hill · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2022 · grant · DP1
Lnc'ing White Fat to Brown Fat Thermogenesis
Carl D Novina · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · research · R37
Molecular mechanisms underlying lineage plasticity in prostate cancer
Himisha Beltran · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · career development · K08
Enhancing Venetoclax Activity in Chemoresistant Acute Myeloid Leukemia
Jacqueline Suen Garcia · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2023 · fellowship · F32
Studies of mutant-selective allosteric inhibitors of EGFR for non-small cell lung cancer
Tyler Steven Beyett · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2022 · career development · K08
Mechanism of Action of Spautin-1, A Novel Degrader of IKZF1
Vidyasagar Koduri · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · research · R01
Targeting of tumor cell DHHC3 to enhance anti-cancer immunity
Martin E Hemler · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2023 · grant · KCRP
Combining Locally Administered Ipilimumab with a Personalized Neoantigen Cancer Vaccine to Improve T-Cell Priming and Antitumor Immunity in High-Risk Renal Cell Carcinoma
Catherine Wu · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2020–2025 · research · R50
Single cell investigation of co-evolution in cancer cells and host cell immune microenvironment
Shuqiang Li · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · research · R01
Targeting of tumor cell DHHC3 to enhance anti-cancer immunity
Martin E Hemler · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020 · research · R01
ATR Dependency as a Novel Therapeutic Target in Lethal RB Deficient Prostate Cancer.
Leigh Ellis · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2024 · fellowship · F32
Identifying Combination Therapies in Ovarian Tumors using High Throughput Dynamic BH3 Profiling
Kelley Mcqueeney · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · program · P50
Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant
Alan D. D'Andrea · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2021 · research · R21
Memory-like NK cells for enhanced immunotherapy of post transplant relapse in patients with myeloid malignancies
Rizwan Romee · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2023 · fellowship · F32
Studies of mutant-selective allosteric inhibitors of EGFR for non-small cell lung cancer
Tyler Steven Beyett · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · program · P01
Biology and structure of pMHC receptors functioning as mechanosensors in the [alpha][beta] T-cell lineage
Matthew J. Lang · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · program · P01
Biology and structure of pMHC receptors functioning as mechanosensors in the [alpha][beta] T-cell lineage
Matthew J. Lang · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2022 · career development · K99
Deep clinical trajectory modeling to optimize accrual to cancer clinical trials
Kenneth L Kehl · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · career development · K08
Mechanism of Action of Spautin-1, A Novel Degrader of IKZF1
Vidyasagar Koduri · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · research · R37
Liquid biopsy approaches to inform osteosarcoma prognosis and tumor evolution
Brian Crompton · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · research · R37
Liquid biopsy approaches to inform osteosarcoma prognosis and tumor evolution
Brian Crompton · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · program · P50
Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant
Alan D. D'Andrea · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2026 · research · R01
Adapting and evaluating a brief advice tobacco intervention in high-reach, low-resource settings in India
Shoba Ramanadhan · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2027 · research · R35
The role of clonal hematopoiesis in the development and therapy of myeloid malignancies
Benjamin Levine Ebert · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2021 · career development · K00
Targeting the Nrf2 pathway in cancer
Di Zhang · Dana-Farber Cancer Institute · funded by National Institutes of Health
2020–2025 · research · R01
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer
Kai W Wucherpfennig · Dana-Farber Cancer Institute · funded by National Institutes of Health
